Nucleic acid vaccine for activating nkg2c+ natural killer cells
AssigneesCharite-Universitatsmedizin Berlin, Deutsches Rheuma-Forschungszentrum Berlin
InventorsChiara Romagnani, Timo Rückert
Life of this patent
Estimating the term…
Abstract
A nucleic acid molecule including: (a) a sequence encoding a human cytomegalovirus (HCMV) UL40 signal peptide, or sequence variant thereof, and (b) an endoplasmic reticulum (ER)-targeting sequence. In a preferred embodiment the nucleic acid molecule further includes a stability inducing motif at its 3′-end. Also disclosed is a pharmaceutical composition including the nucleic acid molecule and a method of treating and/or reducing the risk of a medical condition associated with pathogenic cells expressing HLA-E, including administering a therapeutically effective amount of the nucleic acid molecule to a patient.
Claims20
A nucleic acid molecule, comprising:
- a. a nucleic acid sequence encoding a peptide sequence X10X11X12X13RX14X15X16X17 (SEQ ID NO:29), wherein
- X10 is Threonine, Phenylalanine, Isoleucine, Asparagine, Arginine, Glutamine or Valine,
- X11 is Glycine, Asparagine, Alanine, Leucine or Methionine,
- X12 is Threonine or Proline,
- X13 is Alanine, Tryptophan, Glycine, Proline, Histidine, Asparagine, Aspartic acid, Glutamic acid, Lysine or Serine, R is Arginine,
- X14 is Serine, Glycine or Threonine,
- X15 is Leucine, Valine, Glutamine or Methionine,
- X16 is Tryptophan, Tyrosine, Alanine, Isoleucine, Leucine, Phenylalanine, Valine, Proline, Cysteine or Glycine, and
- X17 is Leucine, Phenylalanine or Isoleucine, and
- b. an endoplasmic reticulum (ER)-targeting sequence.
Dependencies are inferred from the claim text.